Eran Rotem: Thank you, Yehiel. Now, I will provide a summary of CollPlant’s financial results for the first quarter of 2024. We reported revenues of $1.3 million for the quarter, compared to $2.5 million in the same period last year. This decrease in revenues was primarily due to the timing of milestone payments from our partners. Our operating expenses for the quarter were $3.1 million, compared to $2.6 million in the first quarter of 2023. Our net loss for the quarter was $1.9 million, compared to $1.5 million in the same period last year. As of March 31, 2024, CollPlant had cash and cash equivalents of $23.2 million, which we believe is sufficient to fund our operations through the end of 2025. We continue to carefully manage our expenses while investing in the development of our regenerative medical products. We anticipate higher expenses in quarters involving large animal studies and clinical trials, but we remain confident in our ability to manage our cash burn rates effectively. We are in discussions with the FDA to design a pivotal study for our breast implant program, and we expect to report data from ongoing large animal studies in late 2024 and early 2025. Overall, we are pleased with our financial position and the progress we are making in advancing our innovative products. Thank you for joining us today, and we look forward to updating you on our future developments. Now, we will open the call for questions. Thank you.
